These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 23585686)

  • 1. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
    Sobarzo A; Groseth A; Dolnik O; Becker S; Lutwama JJ; Perelman E; Yavelsky V; Muhammad M; Kuehne AI; Marks RS; Dye JM; Lobel L
    J Infect Dis; 2013 Jul; 208(2):299-309. PubMed ID: 23585686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.
    Sobarzo A; Perelman E; Groseth A; Dolnik O; Becker S; Lutwama JJ; Dye JM; Yavelsky V; Lobel L; Marks RS
    Clin Vaccine Immunol; 2012 Nov; 19(11):1844-52. PubMed ID: 22993411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune memory to Sudan virus: comparison between two separate disease outbreaks.
    Sobarzo A; Eskira Y; Herbert AS; Kuehne AI; Stonier SW; Ochayon DE; Fedida-Metula S; Balinandi S; Kislev Y; Tali N; Lewis EC; Lutwama JJ; Dye JM; Yavelsky V; Lobel L
    Viruses; 2015 Jan; 7(1):37-51. PubMed ID: 25569078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.
    Sobarzo A; Stonier SW; Radinsky O; Gelkop S; Kuehne AI; Edri A; Herbert AS; Fedida-Metula S; Lutwama JJ; Yavelsky V; Davis C; Porgador A; Dye JM; Lobel L
    EBioMedicine; 2019 Aug; 46():215-226. PubMed ID: 31326432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors.
    Sobarzo A; Stonier SW; Herbert AS; Ochayon DE; Kuehne AI; Eskira Y; Fedida-Metula S; Tali N; Lewis EC; Egesa M; Cose S; Lutwama JJ; Yavelsky V; Dye JM; Lobel L
    Viruses; 2016 May; 8(5):. PubMed ID: 27187443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.
    Rimoin AW; Lu K; Bramble MS; Steffen I; Doshi RH; Hoff NA; Mukadi P; Nicholson BP; Alfonso VH; Olinger G; Sinai C; Yamamoto LK; Ramirez CM; Okitolonda Wemakoy E; Kebela Illunga B; Pettitt J; Logue J; Bennett RS; Jahrling P; Heymann DL; Piot P; Muyembe-Tamfum JJ; Hensley LE; Simmons G
    J Infect Dis; 2018 Jan; 217(2):223-231. PubMed ID: 29253164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.
    Bramble MS; Hoff N; Gilchuk P; Mukadi P; Lu K; Doshi RH; Steffen I; Nicholson BP; Lipson A; Vashist N; Sinai C; Spencer D; Olinger G; Wemakoy EO; Illunga BK; Pettitt J; Logue J; Marchand J; Varughese J; Bennett RS; Jahrling P; Cavet G; Serafini T; Ollmann Saphire E; Vilain E; Muyembe-Tamfum JJ; Hensely LE; Simmons G; Crowe JE; Rimoin AW
    J Infect Dis; 2018 Nov; 218(12):1929-1936. PubMed ID: 30107445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
    Reynard O; Volchkov VE
    J Infect Dis; 2015 Oct; 212 Suppl 2():S372-8. PubMed ID: 26232760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI.
    Radinsky O; Edri A; Brusilovsky M; Fedida-Metula S; Sobarzo A; Gershoni-Yahalom O; Lutwama J; Dye J; Lobel L; Porgador A
    Sci Rep; 2017 Jul; 7(1):6054. PubMed ID: 28729706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Sudan Virus Ebola Survivors Maintain Multiple Antiviral Defense Mechanisms.
    Sobarzo A; Moné Y; Lang S; Gelkop S; Brangel P; Kuehne AI; McKendry RA; Mell JC; Ahmed A; Davis C; Dye JM; Lutwama JJ; Lobel L; Veas F; Ehrlich GD
    J Infect Dis; 2024 Aug; 230(2):426-437. PubMed ID: 38066574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.
    Qiu X; Alimonti JB; Melito PL; Fernando L; Ströher U; Jones SM
    Clin Immunol; 2011 Nov; 141(2):218-27. PubMed ID: 21925951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
    Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
    Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.
    Chen G; Koellhoffer JF; Zak SE; Frei JC; Liu N; Long H; Ye W; Nagar K; Pan G; Chandran K; Dye JM; Sidhu SS; Lai JR
    ACS Chem Biol; 2014 Oct; 9(10):2263-73. PubMed ID: 25140871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
    Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
    J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for differential neutralization of ebolaviruses.
    Bale S; Dias JM; Fusco ML; Hashiguchi T; Wong AC; Liu T; Keuhne AI; Li S; Woods VL; Chandran K; Dye JM; Saphire EO
    Viruses; 2012 Apr; 4(4):447-70. PubMed ID: 22590681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
    Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
    J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus.
    Ayouba A; Touré A; Butel C; Keita AK; Binetruy F; Sow MS; Foulongne V; Delaporte E; Peeters M
    J Clin Microbiol; 2017 Jan; 55(1):165-176. PubMed ID: 27795350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
    Maruyama T; Rodriguez LL; Jahrling PB; Sanchez A; Khan AS; Nichol ST; Peters CJ; Parren PW; Burton DR
    J Virol; 1999 Jul; 73(7):6024-30. PubMed ID: 10364354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.